Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy

Future Oncology

Volumn 6, Issue 5, 2010, Pages 811-821

  Mollinedo, Faustino ^a   Gajate, Consuelo ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Apoptosis; Cancer therapy; CASMER; Death receptor; Death inducing signaling complex; Edelfosine; Ether phospholipids; Fas CD95; Lipid raft; Mechanism of action

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AVICIN D; CASPASE; CERAMIDE; CHOLESTEROL; CISPLATIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; DEHYDRODIDEMNIN B; EDELFOSINE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLUDARABINE; PERIFOSINE; PROCASPASE 10; PROCASPASE 8; PROTEIN BCL 2; PROTEIN BID; RESVERATROL; RITUXIMAB; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; TRITERPENOID; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; DRUG RESEARCH; DRUG TARGETING; HUMAN; LIPID RAFT; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MEMBRANE MICRODOMAINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77952487833     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.34     Document Type: Review

References (73)

1. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R: Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targets 9, 320-340 (2009).
2. Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175-187 (2002).
3. Mollinedo F: Death receptors in multiple myeloma and therapeutic opportunities (Chapter 25). In: Myeloma Therapy. Pursuing the Plasma Cell. Lonial S (Ed.). Humana Press, NJ, USA, 393-419 (2008).
4. 3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem. 11, 3163-3184 (2004).
5. Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15, 1126-1132 (2009).
6. Qiao L, Wong BC: Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat. 12, 55-64 (2009).
7. Mollinedo F, Gajate C: Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist. Updat. 9, 51-73 (2006).
8. Gajate C, Mollinedo F: Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab. 3, 491-525. (2002).
9. Gaffney EA: The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J. Math. Biol. 48, 375-422 (2004).
10. Dy GK, Adjei AA: Systemic cancer therapy: evolution over the last 60 years. Cancer 113, 1857-1887 (2008).
11. Giantonio BJ: Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat. Rev. Clin. Oncol. 6, 311-312 (2009).
12. Robles AI, Linke SP, Harris CC: The p53 network in lung carcinogenesis. Oncogene 21, 6898-6907 (2002).
13. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100, 57-70 (2000).
14. Mollinedo F, Gajate C: FasL-independent activation of Fas (Chapter 2). In: Fas Signaling. Wajant H (Ed.). Landes Bioscience and Springer Science, TX, USA, 13-27 (2006).
15. Kischkel FC, Hellbardt S, Behrmann I et al.: Cytotoxicity-dependent APO-1 (Fas/CD95) -associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588. (1995). •• Identifes the death-inducing signaling complex as a major complex in apoptosis.
16. Kischkel FC, Lawrence DA, Tinel A et al.: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276, 46639-46646 (2001).
17. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (1998). •• Identifies the BH3-interacting domain death agonist as a bridge between the extrinsic and intrinsic apoptotic signaling pathways.
18. Billen LP, Shamas-Din A, Andrews DW: Bid: a Bax-like BH3 protein. Oncogene 27 (Suppl. 1), S93-S104 (2008).
19. Lovell JF, Billen LP, Bindner S et al.: Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074-1084 (2008).
20. Milhas D, Cuvillier O, Therville N et al.: Caspase-10 triggers Bid cleavage and caspase cascade activation in FasL-induced apoptosis. J. Biol. Chem. 280, 19836-19842 (2005).
21. Fischer U, Stroh C, Schulze-Osthoff K: Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene 25, 152-159 (2006).
22. L. Cancer Res. 57, 1320-1328 (1997).
23. 3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98, 3860-3863 (2001). •• Describes the involvement of co-clustering of Fas/CD95 and lipid rafts in apoptosis and cancer chemotherapy.
24. Simons K, Toomre D: Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31-39 (2000). •• Reports lipid rafts as major players in signal transduction.
25. Munro S: Lipid rafts: elusive or illusive? Cell 115, 377-388 (2003).
26. Hanzal-Bayer MF, Hancock JF: Lipid rafts and membrane traffic. FEBS Lett. 581, 2098-2104 (2007).
27. Gajate C, Fonteriz RI, Cabaner C et al.: Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lip id-induced apoptosis. Int. J. Cancer 85, 674-682 (2000).
28. Gajate C, Del Canto-Janez E, Acuna AU et al.: Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J. Exp. Med. 200, 353-365 (2004). •• Describes the intracellular activation of Fas/CD95, and recruitment of Fas/CD95 and downstream signaling molecules in lipid rafts, as a new mechanism of action in cancer therapy.
29. Zaremberg V, Gajate C, Cacharro LM, Mollinedo F, McMaster CR: Cytotoxicity of an anti-cancer lysophospholipid through selective modifcation of lipid raft composition. J. Biol. Chem. 280, 38047-38058 (2005).
30. Gajate C, Mollinedo F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109, 711-719 (2007). • Describes the role of recruitment of death receptor and downstream signaling molecules in lipid rafts in the treatment of multiple myeloma.
31. Ausili A, Torrecillas A, Aranda FJ et al.: Edelfosine is incorporated into rafts and alters their organization. J. Phys. Chem. B 112, 11643-11654 (2008).
32. Gajate C, Gonzalez-Camacho F, Mollinedo F: Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE 4, E5044 (2009). • Describes the involvement and visualization of the death-inducing signaling complex in lipid raft aggregates in apoptosis and cancer therapy.
33. Gajate C, Mollinedo F: Cytoskeletonmediated death receptor and ligand concentration in lipid rafts forms apoptosispromoting clusters in cancer chemotherapy. J. Biol. Chem. 280, 11641-11647 (2005). • Describes the recruitment of death receptor ligand in lipid rafts, and involvement of actin cytoskeleton in raft-mediated apoptosis.
34. Lacour S, Hammann A, Grazide S et al.: Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64, 3593-3598 (2004).
35. Xu ZX, Ding T, Haridas V, Connolly F, Gutterman JU: Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts. PLoS ONE 4, E8532 (2009).
36. Delmas D, Rebe C, Micheau O et al.: Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23, 8979-8986 (2004).
37. Reis-Sobreiro M, Gajate C, Mollinedo F: Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 28, 3221-3234 (2009).
38. Stel AJ, Ten Cate B, Jacobs S et al.: Fas receptor clustering and involvement of the death receptor pathway in rituximabmediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J. Immunol. 178, 2287-2295 (2007).
39. Nieto-Miguel T, Gajate C, Gonzalez-Camacho F, Mollinedo F: Proapoptotic role of Hsp90 by its interaction with c-Jun. N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. Oncogene 27, 1779-1787 (2008).
40. Gajate C, Gonzalez-Camacho F, Mollinedo F: Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun. 380, 780-784 4 (2009).
41. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH: The role of c-Jun. N-terminal kinase (JNK) in apoptosis induced by ultraviolet C andγ radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem. 271, 31929-31936. (1996).
42. 2-terminal kinase activation and c-Jun. in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-racglycero-3- phosphocholine. Mol. Pharmacol. 53, 602-612 (1998).
43. 3-induced apoptosis of human leukemic cells. Int. J. Cancer 86, 208-218 (2000).
44. Gajate C, An F, Mollinedo F: Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95- and mitochondrial- mediated mechanism. Clin. Cancer Res. 9, 1535-1545 (2003).
45. Freeman MR, Solomon KR: Cholesterol and prostate cancer. J. Cell Biochem. 91, 54-69 (2004).
46. Tosi MR, Tugnoli V: Cholesteryl esters in malignancy. Clin. Chim. Acta 359, 27-45 (2005).
47. Li YC, Park MJ, Ye SK, Kim CW, Kim YN: Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168, 1107-1118 (2006).
48. Buchsbaum DJ, Forero-Torres A, LoBuglio AF: TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol. 3 (4), 405-409 (2007).
49. Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27, 6207-6215 (2008).
50. Kruyt FA: TRAIL and cancer therapy. Cancer Lett. 263, 14-25 (2008).
51. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S: Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin. Cancer Res. 14, 5090-5098 (2008).
52. Ndozangue-Touriguine O, Hamelin J, Breard J: Cytoskeleton and apoptosis. Biochem. Pharmacol. 76, 11-18 (2008).
53. Tsukita S, Yonemura S: Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J. Biol. Chem. 274, 34507-34510 (1999).
54. Bretscher A, Edwards K, Fehon RG: ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3, 586-599 (2002).
55. Fievet B, Louvard D, Arpin M: ERM proteins in epithelial cell organization and functions. Biochim. Biophys. Acta 1773, 653-660 (2007).
56. Parlato S, Giammarioli AM, Logozzi M et al.: CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19, 5123-5134 (2000). •• Describes the linkage of Fas/CD95 to actin cytoskeleton through ezrin as a novel regulatory mechanism in Fas/CD95-mediated apoptosis.
57. Giammarioli AM, Garofalo T, Sorice M et al.: GD3 glycosphingolipid contributes to Fas-mediated apoptosis via association with ezrin cytoskeletal protein. FEBS Lett. 506, 45-50 (2001).
58. Lozupone F, Lugini L, Matarrese P et al.: Identifcation and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem. 279, 9199-9207 (2004).
59. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME: Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22, 207-220 (2002).
60. Hebert M, Potin S, S ebbagh M, Bertoglio J, Breard J, Hamelin J: Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J. Immunol. 181, 5963-5973 (2008).
61. Sorice M, Matarrese P, Tinari A et al.: Raft component GD3 associates with tubulin following CD95/Fas ligation. FASEB J. 23, 3298-3308 (2009).
62. Sorice M, Matarrese P, Manganelli V et al.: Role of GD3-CLIPR-59 association in lymphoblastoid T cell apoptosis triggered by CD95/Fas. PLoS ONE 5, E8567 (2010).
63. Gupta N, Wollscheid B, Watts JD, Scheer B, Aebersold R, DeFranco AL: Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat. Immunol. 7, 625-633 (2006).
64. Zeidan Y. H, Jenkins RW, Hannun YA: Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J. Cell Biol. 181, 335-350 (2008).
65. Prinetti A, Chigorno V, Prioni S et al.: Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J. Biol. Chem. 276, 21136-21145 (2001).
66. Kolesnick R: The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 110, 3-8 (2002).
67. Grassme H, Cremesti A, Kolesnick R, Gulbins E: Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22, 5457-5470 (2003). •• Describes the involvement of ceramide in Fas/CD95 clustering and Fas/CD95-mediated apoptosis.
68. Biswal SS, Datta K, Acquaah-Mensah GK, Kehrer JP: Changes in ceramide and sphingomyelin following fudarabine treatment of human chronic B-cell leukemia cells. Toxicology 154, 45-53 (2000).
69. Hu W, Xu R, Zhang G et al.: Golgi fragmentation is associated with ceramide - induced cellular effects. Mol. Biol. Cell 16, 1555-1567 (2005).
70. Vyas KA, Patel HV, Vyas AA, Schnaar RL: Segregation of gangliosides GM1 and GD3 on cell membranes, isolated membrane rafts, and defned supported lipid monolayers. Biol. Chem. 382, 241-250 (2001).
71. Mishra S, Joshi PG: Lipid raft heterogeneity: an enigma. J. Neurochem. 103 (Suppl. 1), 135-142 (2007).
72. Lingwood D, Kaiser HJ, Levental I, Simons K: Lipid rafts as functional heterogeneity in cell membranes. Biochem. Soc. Trans. 37, 955-960 (2009).
73. Delmas D, Rebe C, Lacour S et al.: Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. 278, 41482-41490 (2003).